Pegvisomant: all 24 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin ResistanceRecruitingNCT05470504Phase 2
- Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetesCompletedNCT02023918Phase 2Results posted
- Effect of DPP4 Inhibition on Growth Hormone SecretionCompletedNCT01701973Phase 4Results posted
- Acromegaly Combination Treatment StudyTerminatedNCT01538966Not applicableResults posted
- Tissue Biomarker for Pegvisomant ActionCompletedNCT01261000Not applicableResults posted
- Figitumumab Combined With Pegvisomant For Advanced Solid TumorsTerminatedNCT00976508Phase 1Results posted
- Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsCompletedNCT00383708Phase 3Results posted
- Safety and Efficacy of Pegvisomant in Children With Growth Hormone ExcessCompletedNCT03882034Phase 3
- Strict IGF-1 Control in AcromegalyCompletedNCT02952885Phase 3
- Pasireotide LAR and Pegvisomant Study in AcromegalyStatus unknownNCT02668172Phase 4
- Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During FastingCompletedNCT02500095Not applicable
- Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone DeficiencyStatus unknownNCT01804413Not applicable
- Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy SubjectsCompletedNCT01181973Phase 1
- The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal PersonsStatus unknownNCT00969644Not applicable
- Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic PatientsCompletedNCT00652379Not applicable
- Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic PatientsCompletedNCT00642720Phase 4
- Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist PegvisomantStatus unknownNCT00552851Phase 4
- Growth Hormone Signaling in Vivo in HumansCompletedNCT00512473Not applicable
- Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid ContentCompletedNCT00476879Not applicable
- Efficacy of Octreotide Acetate and Cabergoline in Patients With AcromegalyCompletedNCT00376064Phase 4
- Long Term Study With B2036-PEGCompletedNCT00143416Phase 3
- A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With AcromegalyCompletedNCT00068042Phase 4
- Pegvisomant And Sandostatin LAR Combination StudyCompletedNCT00068029Phase 4
- A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 3